Cumulus Neuroscience Presents Data at CTAD 2023 Annual Meeting.
ENPNewswire-October 26, 2023--Cumulus Neuroscience Presents Data at CTAD 2023 Annual Meeting
(C)2023 ENPublishing - http://www.enpublishing.co.uk
Release date- 25102023 - Cumulus Neuroscience presented data at the Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting on Wednesday October 25th in Boston, Massachusetts.
Cumulus presented three (3) poster presentations, two featuring internally generated data collected from Cumulus-sponsored studies partnering with academic and clinical institutions, and one featuring data generated from a study sponsored by INmune Bio Inc. (Nasdaq: INMB) a clinical stage biopharma company.
The poster featuring data generated from a Phase Ib study in Alzheimer's Disease (AD) sponsored by INmune Bio titled, 'Feasibility of the Cumulus electrophysiological neurocognitive platform to enable de-centralized trials in Alzheimer's Disease,' demonstrated that the Cumulus Neuroassessment platform can be frequently and accurately used by patients living with mild to moderate AD in the home over long periods of time (e.g., >3 months) including 'burst' measurement periods in-lab or at-home where each cognitive assessment is administered several times in relatively quick succession. The study was carried out during the pandemic, and demonstrated how the system could be used autonomously at-home even by substantially impaired patients, avoiding the need for in-person assessment visits.
These findings are consistent with data presented in a second poster titled, 'A real-world, longitudinal observational study in patients with Alzheimer's Disease dementia and healthy controls, using frequent repeated digital measurements performed at-home on the Cumulus Platform: a preliminary report' which features data from CNS-101, a real-world feasibility study being conducted in collaboration with the Universities of Oxford and Cambridge. Importantly, preliminary analysis of the burst stage indicates these types of digital technologies have construct validity, distinguishing groups, correlating with conventional benchmarks, across behavioral and biosignal endpoints.
A third poster titled, 'Validating a novel digital cognitive platform: sensitivity to change following an alcohol challenge,' featured data from a study focused on validating a new cognitive assessment battery including tasks targeting four cognitive functions affected early in the AD continuum: Double-Take, an N-back working memory test
Memory Match, a paired episodic...
To continue reading
Request your trial